Previous studies have suggested that increase in both EGFR and ERBB3 expression and phosphorylation can be induced after mitogen-activating protein kinase (MAPK) inhibitor treatment [12, 15–20], and that targeting EGFR and ERBB3 can prevent and extend the establishment of MAPK inhibitor-induced resistance in melanoma [12, 15, 17]. The gene discussed is ERBB3; the disease is melanoma.